Older melanoma patients have better response to immune checkpoint blockade therapyJune 13, 2018
PHILADELPHIA -- (June 13, 2018) -- Patient age correlates with response to immunotherapy in melanoma and depleting regulatory T cells in young patients may have a therapeutic potential to enhance response in younger patients, according to research from The Wistar Institute. Study results were published online in Clinical Cancer Research.
Immune checkpoint blockade therapy has been recently approved for treatment of melanoma based on its ability to produce durable disease control. Not all patients benefit from this therapeutic approach and some responders eventually develop resistance, highlighting the need for biomarkers that could help predict patient benefit and guide therapeutic choices.
"We have shown that the characteristics of the aged tumor microenvironment in older patients promote resistance to melanoma targeted therapies, highlighting the importance of considering patient age when predicting response to therapy," said Ashani Weeraratna, Ph.D., Ira Brind Associate Professor and co-program leader of the Immunology, Microenvironment and Metastasis Program at Wistar and corresponding author of the paper.
Based on this consideration, Weeraratna and collaborators set to analyze the impact of age on response to immunotherapy. "We were initially surprised to find that older patients fare better on immune checkpoint blockade therapy," she added.
The researchers analyzed a multi-national, multi-institutional cohort of almost 500 melanoma patients treated with pembrolizumab, an anti-programmed cell death receptor-1 (PD1) checkpoint therapy. They observed a significant difference in response to treatment by age, specifically that older patients had a decreased chance of disease progression after therapy, irrespective of gender and prior treatment with targeted therapies.
This observation was confirmed in mouse models of melanoma. In fact, genetically identical tumors responded more to anti-PD1 treatment when transplanted in old mice than in young mice, suggesting that the difference is ascribable to the environment in which the tumor develops.
The researchers analyzed the immune cell composition of the old and young tumor microenvironment both in patient-derived tissues and in mouse models and found a significant decrease in tumor infiltration of regulatory T cells (Treg) with age. These cells, characterized by expression of the FOXP3 marker, suppress the anti-tumor immune response and reduce response to anticancer immunotherapy. In parallel with a decrease in the percentage of Treg cells, older age correlated with increased presence of killer CD8 T cells, which are the primary effectors in the response to immune checkpoint blockade therapy.
Based on these observations, the researchers depleted Treg cells in the young mouse model by targeting them with an antibody against CD25, which is predominantly expressed at high levels on Treg cells. Combining anti-PD1 and anti-CD25 treatment was significantly more effective than anti-PD1 alone and they obtained response rates similar to those seen in aged mice, suggesting that overcoming the immune suppression observed in the young microenvironment helps to restore sensitivity to immunotherapy.
"Our study shows that age is an important factor to consider when administering immunotherapy to melanoma patients," added Weeraratna. "A combination approach to deplete immune suppressive cells in combination with checkpoint blockade therapy might benefit younger patients, although further studies will be required to evaluate more broadly the potential immune toxicities of this approach."
Co-authors of this study from The Wistar Institute include Stephen M. Douglass, Marie R Webster, Amanpreet Kaur, Qin Liu, Xiangfan Yin, Abibatou Ndoye, Reeti Behera, Gretchen M. Alicea, Brett L. Ecker, Mitchell Fane, Michael J Allegrezza, Nikolaos Svoronos, Vinit Kumar, Rajasekharan Somasundaram, Meenhard Herlyn, Dmitry Gabrilovich, and Erica L Stone. Other co-authors include Sarah A Weiss, Iman Osman and Farbod Darvishian from New York University School of Medicine; Rami N Al-Rohil, Daniel Y Wang, and Douglas B. Johnson from Vanderbilt University Medical Center; Siwen Hu-Lieskovan, Theodore S Nowicki, and Antoni Ribas from University of California Los Angeles; Alpaslan Ozgun, Jose R. Conejo- Garcia, and Zeynep Eroglu from Moffitt Cancer Center; Jeffrey Sosman from Northwestern University; Rajat Rai, Matteo S. Carlino, Georgina V. Long, and Alexander M Menzies from The University of Sydney, Australia; Richard Marais from University of Manchester, UK; Michael A. Davies and Jennifer L. McQuade from The University of Texas MD Anderson Cancer Center; Bastian Schilling and Dirk Schadendorf from University Duisburg-Essen, Germany; Wei Xu and Ravi K. Amaravadi from University of Pennsylvania.
The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. wistar.org.
The Wistar Institute
Related Melanoma Articles:
Researchers at Dartmouth's Norris Cotton Cancer Center find that unique immune cells, called resident memory T cells, do an outstanding job of preventing melanoma in patients who develop the autoimmune disease, vitiligo.
University of Iowa researchers have documented in continuous, real time how melanoma cells form tumors.
A University of Colorado Cancer Center study published March 15, 2017, in the journal Melanoma Research uses the unique resource of over 600 melanoma samples collected at the university to demonstrate, for the first time, novel mutations involved in mucosal melanoma, paving the way for therapies to treat this overlooked subtype.
Newly identified genes and genetic pathways in primary melanoma -- a type of skin cancer -- could give researchers new targets for developing new personalized treatments for melanoma, and potentially other cancers.
A QUT-driven project has identified the way in which melanoma cells spread, opening up new pathways to treatment via drugs to 'turn off' the invasive gene.
A new research letter published online by JAMA Dermatology updates information on trends in melanoma incidence and death in the United States since 2009.
In a paper published online Nov. 30, 2016, in Melanoma Management, Adam Riker, M.D., Professor of Surgery and Chief of Surgical Oncology at LSU Health New Orleans School of Medicine, reviews approaches to manage melanoma, including one tested at LSU Health New Orleans that provoked a complete response in a patient with a long history of the disease.
The latest study of the Melanoma Group at the Spanish National Cancer Research Centre describes the roles of CPEB4; a protein that is crucial for melanoma cell survival.
Changes in the genetic make-up of tissue samples can be detected quickly and easily using a new method based on nanotechnology.
Colorado State University Professor Jesse Wilson has received a one-year, $30,000 grant from the Colorado Clinical and Translational Sciences Institute to develop a new microscope that can distinguish between benign and malignant pigmented skin lesions, without the need for biopsy.
Related Melanoma Reading:
Melanoma: A Modern Multidisciplinary Approach
by Adam I. Riker (Editor)
This text serves as a very useful clinical guide and realistic approach to the clinical management of melanoma. Primary care physicians, specialists from varying areas of medical practice and numerous other healthcare providers will find this text to be quite useful as a standard daily reference and use in the office setting. It provides a clear and concise source of information in order to make real-life, evidence-based decisions for all aspects of management for cutaneous melanoma. This book also provides the latest breakthroughs in melanoma research, ranging from recent discoveries in... View Details
Melanoma- Not Just Skin Cancer
by Catherine M. Poole (Author)
All cancer diagnoses are terrifying, but a melanoma diagnosis is both frightening and confusing. When Catherine M. Poole learned she had melanoma twenty-five years ago, she found that most of the literature on melanoma focused on prevention. To add to her understandable alarm, she couldn’t find clear, concise information on treatment options. Poole wanted to be an informed patient, but she had no resources.
She survived melanoma and has become a dedicated activist for melanoma research and a staunch patient advocate. Her new book, Melanoma: Not Just Skin Cancer, is a... View Details
Melanoma without a Cause: How the New Miracle Immunotherapy Drugs and My Own Immune System Helped Me Fight Stage Four Cancer
by Bryant Wieneke (Author)
Melanoma without a Cause: How the New Miracle Immunotherapy Drugs and My Own Immune System Helped Me Fight Stage Four Cancer is a tale of survival following a devastating diagnosis of metastatic melanoma. Fighting through some heavy side effects, the author is saved by a treatment not available even a few years ago. He is given immunotherapy drugs, which stimulate his immune system to target and destroy the cancer cells that have spread throughout his body. Melanoma with a Cause chronicles the author’s treatment and remarkable turnaround, but remission remains elusive. A blog has been... View Details
Beating Melanoma: A Five-Step Survival Guide (A Johns Hopkins Press Health Book)
by Steven Q. Wang MD (Author)
Dr. Steven Q. Wang, a world-renowned skin cancer expert, provides an essential guide for people with melanoma and their families.
The book’s unique, practical format approaches the disease in two phases, just as people with melanoma need to do. First comes a step-by-step guide for what Dr. Wang calls the "mad rush" phase―an intense and stressful period from diagnosis to completing initial treatment. Dr. Wang's calm guidance helps readers through this critical time, using an easy to understand plan for ensuring optimal treatment and survival outcomes. Once the mad rush phase is... View Details
Healing Melanoma - The Gerson Way
by Charlotte Gerson (Author)
This booklet introduces Dr. Max Gerson and the founding principal of the Gerson Therapy, that Melanoma and most chronic diseases are able to manifest in the body because of toxicity and nutritional deficiency. Charlotte Gerson gives an overview of the Gerson Therapy and reviews some of the methods used in the program. Also included are case histories of individuals confronted with Melanoma and how they overcame then using the Gerson Therapy.View Details
Melanoma: It Started With a Freckle
by David L. Stanley (Author)
With "Melanoma: It Started with a Freckle", David L. Stanley invites you to join him on an inside tour of his cancer. You'll travel with Stanley from the dimly lit and elegantly decorated office of the dermatologist to the fluorescent glare of the operating room theater and back to the workplace as he faces up to melanoma, the only major cancer that has seen its incidence rise since 2000, with humor, humility, and a deep understanding of the disease borne of research and science. In a memoir that speaks to anyone who has bumped up against a major health scare, Stanley offers up an engaging... View Details
The Melanoma Book: A Complete Guide to Prevention and Treatment, Including theEarly DetectionSelf-Exam Body Map
by Howard L. Kaufman (Author)
Citing high rates of cures that can be achieved with early detection, a whole-life plan informs readers on how to best enable melanoma skin cancer's immediate detection and select the most compatible and effective treatment options. Original. View Details
by Jonathan S. Zager (Editor), Vernon K. Sondak (Editor), Ragini Kudchadkar (Editor)
Melanoma is a concise handbook that identifies best-practice guidelines and presents the most current procedures for the diagnosis and management of melanoma in a succinct and easy-to-read manner. Chapters cover melanoma pathology, biopsy techniques, staging and risk stratification, surgical treatment of localized melanoma, immunotherapy, radiation therapy, and guidelines for resected melanoma, targeted therapy, cytotoxic chemotherapy, and management of brain metastases, mucosal and ocular melanoma, and pediatric melanoma patients. This handbook is a must-have tool for clinicians... View Details
A Melanoma Patient's Survival Guide: Lemons Really Do Make Lemonade: You Just Have to Add a Little Sugar
by Sally Welsh (Author)
A Melanoma Patient’s Survival guide: Lemons Really Do Make Lemonade is an effort to bring awareness to the subject of melanoma. This insidious disease is being diagnosed in over 50,000 people a year in the United States alone. Melanoma will affect one in seventy-five people in California. That rate goes up each year. Melanoma can be a silent killer. This heart-warming book was written by a survivor of serious melanoma, Sally Welsh. Sally has shared her experience with thousands of people, and has prepared this book with the hope of making your journey a little easier. Her suggestions deal... View Details
Melanoma Messed With the Wrong Person: Blank Lined Journal - 6x9 - Gift for Melanoma Patient or Melanoma Survivor
by Passion Imagination Journals (Author)
Are you looking for a beautiful, humorous gift for someone who has Melanoma or a Melanoma survivor?
This is a blank, lined journal that makes a perfect present for friends and family, male or female. Other features of this notebook include:
110 pages6x9 inchesExcellent and thick bindingDurable white paperSleek, matte-finished cover for a professional look
This diary is a convenient and perfect size to carry anywhere for writing, journaling and note taking. If you would like an unlined journal or a different cover, please take a look at our other... View Details